open access

Vol 67, No 1 (2017)
Research paper (original)
Published online: 2017-08-24
Get Citation

Typical medullary breast carcinoma: clinical outcomes and treatment results

Andrzej Stelmach, Janusz Ryś, Jerzy W. Mituś, Anna Patla, Piotr Skotnicki, Marian Reinfuss, Elżbieta Pluta, Tomasz Walasek, Beata Sas-Korczyńska
DOI: 10.5603/NJO.2017.0002
·
Nowotwory. Journal of Oncology 2017;67(1):7-13.

open access

Vol 67, No 1 (2017)
Original article
Published online: 2017-08-24

Abstract

Typical medullary breast carcinoma (T-MBC) accounts for less than 1% of all malignant breast neoplasms, and immu­nohistochemically is characteristic of “triple-negative” breast carcinoma. The purpose of this study was to describe the clinical characteristics and treatment results for patients with T-MBC treated at a single institution, and discuss the controversial aspects of this very rare form of breast cancer. Analyses was performed in 120 patients with T-MBC who were treated between 1970 and 2005. These cases represent 1.1% of all (11 270) patients treated for breast cancer during this period. According to TNM classification, 26 patients (21.6%) were in stage I, 80 patients (66.7%) in stage II and 14 (11.7%) in stage III of clinically advanced breast cancer. Involved axillary lymph nodes occurred in just 10 (8.3%) of the patients, and in all cases metastases were observed in 1–3 lymph nodes. All the patients un­derwent primary surgery. Radical mastectomies were performed on 98 (81.6%) patients, while the other 22 (18.4%) underwent breast-conserving surgery (BCS). Radiotherapy was performed in 36 patients (22 after BCS and 14 after mastectomy). Patients with nodal involvement (10 patients) received adjuvant chemotherapy, and 8 patients with hormone receptor expression received hormonotherapy with tamoxifen. The 10-year DFS rate was 90%. Out of 120 patients with T-MBC, only 4 (3.3%) died from this cancer. We showed that none of the population, neither clinical nor microscopic, had a statistically significant influence on the 10-year disease-free survival rate. Our results are similar to others presented in literature.

Abstract

Typical medullary breast carcinoma (T-MBC) accounts for less than 1% of all malignant breast neoplasms, and immu­nohistochemically is characteristic of “triple-negative” breast carcinoma. The purpose of this study was to describe the clinical characteristics and treatment results for patients with T-MBC treated at a single institution, and discuss the controversial aspects of this very rare form of breast cancer. Analyses was performed in 120 patients with T-MBC who were treated between 1970 and 2005. These cases represent 1.1% of all (11 270) patients treated for breast cancer during this period. According to TNM classification, 26 patients (21.6%) were in stage I, 80 patients (66.7%) in stage II and 14 (11.7%) in stage III of clinically advanced breast cancer. Involved axillary lymph nodes occurred in just 10 (8.3%) of the patients, and in all cases metastases were observed in 1–3 lymph nodes. All the patients un­derwent primary surgery. Radical mastectomies were performed on 98 (81.6%) patients, while the other 22 (18.4%) underwent breast-conserving surgery (BCS). Radiotherapy was performed in 36 patients (22 after BCS and 14 after mastectomy). Patients with nodal involvement (10 patients) received adjuvant chemotherapy, and 8 patients with hormone receptor expression received hormonotherapy with tamoxifen. The 10-year DFS rate was 90%. Out of 120 patients with T-MBC, only 4 (3.3%) died from this cancer. We showed that none of the population, neither clinical nor microscopic, had a statistically significant influence on the 10-year disease-free survival rate. Our results are similar to others presented in literature.

Get Citation

Keywords

breast cancer, typical medullary carcinoma, outcome, treatment results

About this article
Title

Typical medullary breast carcinoma: clinical outcomes and treatment results

Journal

Nowotwory. Journal of Oncology

Issue

Vol 67, No 1 (2017)

Article type

Research paper (original)

Pages

7-13

Published online

2017-08-24

DOI

10.5603/NJO.2017.0002

Bibliographic record

Nowotwory. Journal of Oncology 2017;67(1):7-13.

Keywords

breast cancer
typical medullary carcinoma
outcome
treatment results

Authors

Andrzej Stelmach
Janusz Ryś
Jerzy W. Mituś
Anna Patla
Piotr Skotnicki
Marian Reinfuss
Elżbieta Pluta
Tomasz Walasek
Beata Sas-Korczyńska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl